2021 global life sciences outlook
Possibility is now reality, sustaining forward momentum
Navigating the pandemic has been an all-encompassing, once-in-a-lifetime challenge. Globally, life sciences companies responded with leadership and are emerging stronger. How will life sciences companies continue to respond and what areas can they build resiliency going forward?
Embracing the future of work to unlock R&D productivity
Measuring the return from pharmaceutical innovation 2018
The biopharma industry continues to face challenges this year, with projected returns on investment in R&D at the lowest levels since our analysis began in 2010. Can this trend be reversed?
The future awakens
Life Sciences and Health Care Predictions 2022
The year is 2022. The quantified self is alive and well, digital technologies have transformed the culture of health care and new entrants have disrupted delivery models. These are some of our predictions that, if they come true, will shake up the life sciences and health care industry.
Time to care
Securing a future for the hospital workforce in Europe
In light of rising demand, staff shortages and lack of time for hands-on-care, is the current hospital workforce model sustainable? New research released by the Deloitte UK Centre for Health Solutions explores the current state of hospital workforces across Europe and their key challenges.
Pharma and the connected patient
How digital technology is enabling patient centricity
New research released by the Deloitte UK Centre for Health Solutions explores how digital technology can help pharma embrace patient centricity to remain relevant, profitable, and to deliver better health outcomes.
Under the spotlight
Data integrity in life sciences
Regulatory bodies now have high expectations with regard to data quality and integrity owing to the life sciences industry’s growth, globalization and adoption of advanced technology, such as highly automated systems and storage of data in ‘The Cloud’. Read the report to learn more.